Not exact matches
While it has shown
promise for some
types of tumors and become standard
of care for others, researchers are just beginning to explore how different
immunotherapy technologies can be applied to brain cancer.
Pharmaceutical giant Merck's flagship
immunotherapy drug that was just approved by the United States Food and Drug Administration (FDA) shows
promise in the overall survival rate among patients suffering from one
of the deadliest
type of cancer that affects the lungs.
The research presentations cover a wide range
of disciplines, treatment approaches and cancer
types, including a unique form
of immunotherapy for ovarian cancer,
promising results on a new treatment approach for Hodgkin lymphoma in children and young adults and an effort to build a predictive tool to determine which patients are most likely to respond well to checkpoint inhibitors.